BCL2 and neoplasm: First, the dual targeting of CDK4/6 and BCL-2 following endocrine therapy (venetoclax, palbociclib, and fulvestrant triple therapy) has been demonstrated to confer superior sustained tumor responses with suitable tolerance in vivo and in vitro compared with single- or double-drug treatment for ER-positive breast tumors [129].